Cystic fibrosis (CF) is caused by mutations in the chloride channel CFTR, which disrupts fluid transport in the lungs. CF patients have a variety of complications, including airway obstruction, infection, and pathological tissue remodeling. Alterations in airway smooth muscle have been observed in CF patients but it is not clear if these abnormalities are directly due to loss of CFTR in airway smooth muscle cells. In this issue of JCI Insight , David Stoltz of the University of Iowa and colleagues provide evidence that CTFR dysfunction directly alters the elasticity and blood supply of the airway. The authors evaluated smooth muscle function in a cohort of CF patients before and immediately after treatment with ivacaftor, which restores CFTR function in this set of patients. Treatment rapidly restored CFTR function, improved airflow, and increased the capacity and flexibility of small airways. The results of this study indicate that loss of CFTR in airway smooth muscle is responsible for some CF-associated symptoms.
###
TITLE:
Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities
AUTHOR CONTACT:
David Stoltz
University of Iowa
Email: david-stoltz@uiowa.edu
Edward F. McKone,
St. Vincent's University Hospital and University College Dublin School of Medicine, E-Email: e.mckone@svuh.ie
View this article at: http://insight.jci.org/articles/view/86183?key=aa28b0157ecd3b474db8
JCI Insight is the newest publication from the American Society of Clinical Investigation, a nonprofit honor organization of physician-scientists. JCI Insight is dedicated to publishing a range of translational biomedical research with an emphasis on rigorous experimental methods and data reporting. All articles published in JCI Insight are freely available at the time of publication. For more information about JCI Insight and all of the latest articles go to http://www.insight.jci.org .
JCI Insight